The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AGIOS PHARMACEUTICALS INC | COM | 00847X104 | 25,756,826 | 579,717 | SH | SOLE | 579,717 | 0 | 0 | |||
| ANIKA THERAPEUTICS INC | COM | 035255108 | 35,447,711 | 1,435,130 | SH | SOLE | 1,435,130 | 0 | 0 | |||
| BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 19,635,246 | 2,583,585 | SH | SOLE | 2,583,585 | 0 | 0 | |||
| ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 3,340,613 | 322,453 | SH | SOLE | 322,453 | 0 | 0 | |||
| EVOLUS INC | COM | 30052C107 | 35,534,506 | 2,193,488 | SH | SOLE | 2,193,488 | 0 | 0 | |||
| EXELIXIS INC | COM | 30161Q104 | 39,592,694 | 1,525,730 | SH | SOLE | 1,525,730 | 0 | 0 | |||
| I MAB | SPONSORED ADS | 44975P103 | 4,339,169 | 3,499,330 | SH | SOLE | 3,499,330 | 0 | 0 | |||
| LIQUIDIA CORPORATION | COM NEW | 53635D202 | 81,185,920 | 8,118,592 | SH | SOLE | 8,118,592 | 0 | 0 | |||
| MINERALYS THERAPEUTICS INC | COM | 603170101 | 11,881,787 | 981,155 | SH | SOLE | 981,155 | 0 | 0 | |||
| OUTLOOK THERAPEUTICS INC | COM | 69012T305 | 1,701,853 | 318,699 | SH | SOLE | 318,699 | 0 | 0 | |||
| VERONA PHARMA PLC | SPONSORED ADS | 925050106 | 41,338,980 | 1,436,878 | SH | SOLE | 1,436,878 | 0 | 0 | |||
| Y-MABS THERAPEUTICS INC | COM | 984241109 | 15,717,577 | 1,195,253 | SH | SOLE | 1,195,253 | 0 | 0 | |||